This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men
Slinin, Y.,
Paudel, M. L.,
Taylor, B. C.,
Fink, H. A.,
Ishani, A.,
Canales, M. T.,
Yaffe, K.,
Barrett-Connor, E.,
Orwoll, E. S.,
Shikany, J. M.,
LeBlanc, E. S.,
Cauley, J. A.,
Ensrud, K. E.
Objective: To test the hypothesis that lower 25-hydroxyvitamin D [25(OH)D] levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline.; Methods: We measured 25(OH)D and assessed cognitive function using the Modified Mini-Mental State Examination (3MS) and Trail Making Test Part B (Trails B) in a cohort of 1,604 men enrolled […]
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study
Sink, Kaycee M.,
Leng, Xiaoyan,
Williamson, Jeff,
Kritchevsky, Stephen B.,
Yaffe, Kristine,
Kuller, Lewis,
Yasar, Sevil,
Atkinson, Hal,
Robbins, Mike,
Psaty, Bruce,
Goff, David C.
Background: Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.; Methods: Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; […]
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET
Shokouhi, S.,
Claassen, D.,
Kang, H.,
Ding, Z.,
Rogers, B.,
Mishra, A.,
Riddle, W. R.
Unlabelled: Evaluating the symptomatic progression of mild cognitive impairment (MCI) caused by Alzheimer disease (AD) is practically accomplished by tracking performance on cognitive tasks, such as the Alzheimer Disease Assessment Scale’s cognitive subscale (ADAS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ). The longitudinal relationships between cognitive decline and metabolic function as […]
A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease
Shinto, Lynne,
Quinn, Joseph,
Montine, Thomas,
Dodge, Hiroko H.,
Woodward, William,
Baldauf-Wagner, Sara,
Waichunas, Dana,
Bumgarner, Lauren,
Bourdette, Dennis,
Silbert, Lisa,
Kaye, Jeffrey
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer’s disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid […]
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Shaw, Leslie M.,
Vanderstichele, Hugo,
Knapik-Czajka, Malgorzata,
Figurski, Michal,
Coart, Els,
Blennow, Kaj,
Soares, Holly,
Simon, Adam J.,
Lewczuk, Piotr,
Dean, Robert A.,
Siemers, Eric,
Potter, William,
Lee, Virginia M.-Y.,
Trojanowski, John Q.
The close correlation between abnormally low pre-mortem cerebrospinal fluid (CSF) concentrations of amyloid-β1-42 (Aβ(1-42)) and plaque burden measured by amyloid imaging as well as between pathologically increased levels of CSF tau and the extent of neurodegeneration measured by MRI has led to growing interest in using these biomarkers to predict the presence of AD plaque […]
Relation of hemoglobin to level of cognitive function in older persons
Shah, Raj C.,
Wilson, Robert S.,
Tang, Yuxiao,
Dong, Xinqi,
Murray, Anne,
Bennett, David A.
Background: While decreased hemoglobin concentration is common in the elderly, the relationship of the entire range of hemoglobin concentrations with cognitive function is not well understood.; Methods: Cross-sectional analyses were conducted utilizing data from community-dwelling, older persons participating in the Rush Memory and Aging Project. Proximate to first available hemoglobin measurement, 21 cognitive tests were […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]
Measuring the experience and perception of suffering
Schulz, R.,
Monin, J. K.,
Czaja, S. J.,
Lingler, J. H.,
Beach, S. R.,
Martire, L. M.,
Dodds, A.,
Hebert, R. S.,
Zdaniuk, B.,
Cook, T. B.
Purpose: assess psychometric properties of scales developed to assess experience and perception of physical, psychological, and existential suffering in older individuals.; Design and Methods: scales were administered to 3 populations of older persons and/or their family caregivers: individuals with Alzheimer’s disease (AD) and their family caregivers (N = 105 dyads), married couples in whom 1 […]